{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:55:37Z","timestamp":1789606537733,"version":"build-2803163510"},"reference-count":24,"publisher":"Siapec Servizi Srl","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-1098","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T12:34:24Z","timestamp":1751978064000},"page":"258-268","source":"Crossref","is-referenced-by-count":2,"title":["Homologous recombination deficiency testing in ovarian cancer: the diagnostic experience of a referral Italian institution"],"prefix":"10.32074","volume":"117","author":[{"given":"Francesco","family":"Pepe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo","family":"Cefaliello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Lamia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Buonaiuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Crimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Scimone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Roscigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"De Finis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Fiordelisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Giampaolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Troncone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2025,6]]},"reference":[{"key":"10.32074\/1591-951X-1098_ref1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.\nhttps:\/\/doi.org\/10.3322\/caac.21551","DOI":"10.3322\/caac.21551"},{"key":"10.32074\/1591-951X-1098_ref2","doi-asserted-by":"crossref","unstructured":"Punz\u00f3n-Jim\u00e9nez P, Lago V, Domingo S, Sim\u00f3n C, Mas A. Molecular Management of High-Grade Serous Ovarian Carcinoma. Int J Mol Sci. 2022;23:13777\nhttps:\/\/doi.org\/10.3390\/ijms232213777","DOI":"10.3390\/ijms232213777"},{"key":"10.32074\/1591-951X-1098_ref3","doi-asserted-by":"crossref","unstructured":"Tsonis O, Gkrozou F, Vlachos K, et al. Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence. Ann Transl Med. 2020;8:1707\nhttps:\/\/doi.org\/10.21037\/atm-20-1620","DOI":"10.21037\/atm-20-1620"},{"key":"10.32074\/1591-951X-1098_ref4","doi-asserted-by":"crossref","unstructured":"Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009;27:2686-2691\nhttps:\/\/doi.org\/10.1200\/JCO.2008.19.2963","DOI":"10.1200\/JCO.2008.19.2963"},{"key":"10.32074\/1591-951X-1098_ref5","doi-asserted-by":"crossref","unstructured":"Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379:2495-2505.\nhttps:\/\/doi.org\/10.1056\/NEJMoa1810858","DOI":"10.1056\/NEJMoa1810858"},{"key":"10.32074\/1591-951X-1098_ref6","doi-asserted-by":"crossref","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol. 2017;18(9):e510]. Lancet Oncol. 2017;18:1274-1284.\nhttps:\/\/doi.org\/10.1016\/S1470-2045(17)30469-2","DOI":"10.1016\/S1470-2045(17)30469-2"},{"key":"10.32074\/1591-951X-1098_ref7","doi-asserted-by":"crossref","unstructured":"Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2017;390(10106):1948]. Lancet. 2017;390(10106):1949-1961.\nhttps:\/\/doi.org\/10.1016\/S0140-6736(17)32440-6","DOI":"10.1016\/S0140-6736(17)32440-6"},{"key":"10.32074\/1591-951X-1098_ref8","doi-asserted-by":"crossref","unstructured":"Dann RB, DeLoia JA, Timms KM, et al. BRCA1\/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2012;125:677-682.\nhttps:\/\/doi.org\/10.1016\/j.ygyno.2012.03.006","DOI":"10.1016\/j.ygyno.2012.03.006"},{"key":"10.32074\/1591-951X-1098_ref9","doi-asserted-by":"crossref","unstructured":"Ngoi NYL, Tan DSP. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?. ESMO Open. 2021;6:100144.\nhttps:\/\/doi.org\/10.1016\/j.esmoop.2021.100144","DOI":"10.1016\/j.esmoop.2021.100144"},{"key":"10.32074\/1591-951X-1098_ref10","doi-asserted-by":"crossref","unstructured":"Wang M, Wu W, Wu W, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006;34:6170-6182.\nhttps:\/\/doi.org\/10.1093\/nar\/gkl840","DOI":"10.1093\/nar\/gkl840"},{"key":"10.32074\/1591-951X-1098_ref11","doi-asserted-by":"crossref","unstructured":"Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366-374.\nhttps:\/\/doi.org\/10.1038\/35077232","DOI":"10.1038\/35077232"},{"key":"10.32074\/1591-951X-1098_ref12","doi-asserted-by":"crossref","unstructured":"Banerjee S, Moore KN, Colombo N, et al. 811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f\/u) from SOLO1. Ann Oncol. 2020;31:S551-S589.\nhttps:\/\/doi.org\/10.1016\/j.annonc.2020.08.950","DOI":"10.1016\/j.annonc.2020.08.950"},{"key":"10.32074\/1591-951X-1098_ref13","doi-asserted-by":"crossref","unstructured":"Oaknin A, Moore K, Colombo N, et al. 4350 e Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola) e Phase III SOLO1 trial. Ann Oncol. 2019;30:v403-v434\nhttps:\/\/doi.org\/10.1093\/annonc\/mdz250.003","DOI":"10.1093\/annonc\/mdz250.003"},{"key":"10.32074\/1591-951X-1098_ref14","doi-asserted-by":"crossref","unstructured":"Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381:2416-2428.\nhttps:\/\/doi.org\/10.1056\/NEJMoa1911361","DOI":"10.1056\/NEJMoa1911361"},{"key":"10.32074\/1591-951X-1098_ref15","doi-asserted-by":"crossref","unstructured":"Timms KM, Mills GB, Perry M, et al. Comparison of genomic instability test scores used for predicting PARP activity in ovarian cancer. J Clin Oncol. 2020;38:1586\nhttps:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.1586","DOI":"10.1200\/JCO.2020.38.15_suppl.1586"},{"key":"10.32074\/1591-951X-1098_ref16","doi-asserted-by":"crossref","unstructured":"Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107:1776-1782.\nhttps:\/\/doi.org\/10.1038\/bjc.2012.451","DOI":"10.1038\/bjc.2012.451"},{"key":"10.32074\/1591-951X-1098_ref17","doi-asserted-by":"crossref","unstructured":"Birkbak NJ, Wang ZC, Kim JY, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents [published correction appears in Cancer Discov. 2013 Aug;3(8):952]. Cancer Discov. 2012;2:366-375.\nhttps:\/\/doi.org\/10.1158\/2159-8290.CD-11-0206","DOI":"10.1158\/2159-8290.CD-11-0206"},{"key":"10.32074\/1591-951X-1098_ref18","doi-asserted-by":"crossref","unstructured":"Mangogna A, Munari G, Pepe F, Maffii E, Giampaolino P, Ricci G, Fassan M, Malapelle U, Biffi S. Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches. J Pers Med. 2023;13:284\nhttps:\/\/doi.org\/10.3390\/jpm13020284","DOI":"10.3390\/jpm13020284"},{"key":"10.32074\/1591-951X-1098_ref19","doi-asserted-by":"crossref","unstructured":"Pepe F, Guerini-Rocco E, Fassan M, Fusco N, Vacirca D, Ranghiero A, Venetis K, Rappa A, Taormina SV, Russo G, Rebellato E, Munari G, Moreno-Manuel A, De Angelis C, Zamagni C, Valabrega G, Malapelle U, Troncone G, Barberis M, Iaccarino A. In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study. J Clin Pathol. 2023:jcp-2023-208852\nhttps:\/\/doi.org\/10.1136\/jcp-2023-208852","DOI":"10.1136\/jcp-2023-208852"},{"key":"10.32074\/1591-951X-1098_ref20","unstructured":"Li W, Gao L, Yi X, et al.Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency. Genomics Proteomics Bioinformatics. 2023:S1672-0229(23)00036-0"},{"key":"10.32074\/1591-951X-1098_ref21","doi-asserted-by":"crossref","unstructured":"Leichsenring J, Horak P, Kreutzfeldt S, et al. Variant classification in precision oncology. Int J Cancer. 2019;145:2996-3010\nhttps:\/\/doi.org\/10.1002\/ijc.32358","DOI":"10.1002\/ijc.32358"},{"key":"10.32074\/1591-951X-1098_ref22","doi-asserted-by":"crossref","unstructured":"Malapelle U, Parente P, Pepe F, De Luca C, Cerino P, Covelli C, Balestrieri M, Russo G, Bonfitto A, Pisapia P, Fiordelisi F, D\u2019Armiento M, Bruzzese D, Loupakis F, Pietrantonio F, Triassi M, Fassan M, Troncone G, Graziano P. Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. Cells. 2020;9:2019\nhttps:\/\/doi.org\/10.3390\/cells9092019","DOI":"10.3390\/cells9092019"},{"key":"10.32074\/1591-951X-1098_ref23","doi-asserted-by":"crossref","unstructured":"Cojocaru E, Parkinson CA, Brenton JD. Personalising Treatment for High-Grade Serous Ovarian Carcinoma. Clin Oncol (R Coll Radiol). 2018;30:515-524\nhttps:\/\/doi.org\/10.1016\/j.clon.2018.05.008","DOI":"10.1016\/j.clon.2018.05.008"},{"key":"10.32074\/1591-951X-1098_ref24","doi-asserted-by":"crossref","unstructured":"Malentacchi F, Ciniselli CM, Pazzagli M, Verderio P, Barraud L, Hartmann CC, Pizzamiglio S, Weisbuch S, Wyrich R, Gelmini S. Influence of pre-analytical procedures on genomic DNA integrity in blood samples: the SPIDIA experience. Clin Chim Acta. 2015;440:205-10\nhttps:\/\/doi.org\/10.1016\/j.cca.2014.12.004","DOI":"10.1016\/j.cca.2014.12.004"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/1481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T13:03:19Z","timestamp":1751979799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pathologica.it\/article\/view\/1481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-1098","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}